How big is REGENXBIO, Inc.?

As of Jun 18, REGENXBIO, Inc. has a market capitalization of 436.37 million, with net sales of 156.72 million and a net profit of -157.70 million over the latest four quarters. The company reported shareholder's funds of 259.65 million and total assets of 465.99 million as of Dec 24.

Market Cap: As of Jun 18, REGENXBIO, Inc. has a market capitalization of 436.37 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, REGENXBIO, Inc. reported net sales of 156.72 million and a net profit of -157.70 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 259.65 million and total assets of 465.99 million.

What does REGENXBIO, Inc. do?

REGENXBIO, Inc. is a clinical-stage biotechnology company focused on gene therapy to address genetic defects. As of March 2025, it reported net sales of $89 million and a market cap of $436.37 million.

Overview: <BR>REGENXBIO, Inc. is a clinical-stage biotechnology company in the Pharmaceuticals & Biotechnology industry, focusing on gene therapy product candidates designed to address genetic defects and enable therapeutic protein production.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 89 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 6 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 436.37 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.75 <BR>Return on Equity: -57.51% <BR>Price to Book: 1.59<BR><BR>Contact Details: <BR>Address: 9600 Blackwell Rd Ste 210, ROCKVILLE MD: 20850-3655 <BR>Tel: 1 240 5528181 <BR>Fax: 1 302 6555049 <BR>Website: http://regenxbio.com/

Should I buy, sell or hold REGENXBIO, Inc.?

Who are in the management team of REGENXBIO, Inc.?

As of March 2022, the management team of REGENXBIO, Inc. includes Chairman Allan Fox, CEO Kenneth Mills, Lead Independent Director A. N. Karabelas, and independent directors Daniel Abdun-Nabi, Luke Beshar, Alexandra Glucksmann, and David Stump. This team provides governance and strategic direction for the company.

As of March 2022, the management team of REGENXBIO, Inc. includes the following individuals:<BR><BR>- Mr. Allan Fox, Chairman of the Board<BR>- Mr. Kenneth Mills, President, Chief Executive Officer, Executive Director<BR>- Dr. A. N. Karabelas, Lead Independent Director<BR>- Mr. Daniel Abdun-Nabi, Independent Director<BR>- Mr. Luke Beshar, Independent Director<BR>- Ms. Alexandra Glucksmann, Independent Director<BR>- Dr. David Stump, Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Is REGENXBIO, Inc. overvalued or undervalued?

As of February 28, 2023, REGENXBIO, Inc. is considered overvalued with a risky financial outlook, reflected by poor return metrics and significant underperformance compared to the S&P 500.

As of 28 February 2023, the valuation grade for REGENXBIO, Inc. moved from fair to risky, indicating a deterioration in its financial outlook. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 1.76 and an EV to Sales ratio of 1.76, which suggest that the market is pricing the stock higher than its underlying value. Additionally, the negative ROCE of -231.58% and ROE of -57.51% further highlight the company's struggles in generating returns for shareholders.<BR><BR>In comparison to peers, Keros Therapeutics, Inc. has a P/E ratio of 33.47, while Revance Therapeutics, Inc. shows a risky valuation with an EV to EBITDA of -4.03, underscoring the challenges faced by REGENXBIO. The company's stock has underperformed significantly over the long term, with a 5-year return of -68.75% compared to a 96.61% return for the S&P 500, reinforcing the notion that REGENXBIO is overvalued in its current state.

Is REGENXBIO, Inc. technically bullish or bearish?

As of August 25, 2025, REGENXBIO, Inc. shows a mildly bullish technical trend, supported by bullish daily moving averages and a weekly MACD, despite mixed indicators on longer timeframes and a year-to-date return of 21.09% compared to the S&P 500's 12.22%.

As of 25 August 2025, the technical trend for REGENXBIO, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages are bullish, but the weekly and monthly KST indicators show a mildly bearish stance. The Bollinger Bands indicate a bullish trend on the weekly chart but a mildly bearish trend on the monthly chart. Dow Theory reflects a mildly bullish outlook on the weekly basis, contrasting with a mildly bearish view on the monthly. The On-Balance Volume is mildly bearish for both weekly and monthly periods.<BR><BR>In terms of performance, REGENXBIO has a year-to-date return of 21.09%, significantly outperforming the S&P 500's 12.22%, but it has underperformed over the longer term, with a one-year return of -25.30% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, driven primarily by the bullish daily moving averages and the weekly MACD.